相关实验视频

Updated: Jun 25, 2025

Development of Compendium for Esophageal Squamous Cell Carcinoma

Development of Compendium for Esophageal Squamous Cell Carcinoma

Published on: April 12, 2024

在食道癌发育过程中对受CYP4F12调控的素乙化的综合分析

Yanhong Chen¹, Li Wang¹, Yuchen Wang¹

¹Institute of Drug Metabolism and Pharmaceutical Analysis, Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, Cancer Center of Zhejiang University, College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China (Y.C., Y.W., Y.F., S.Z.); and Key Laboratory of Novel Targets and Drug Study for Neural Repair of Zhejiang Province, School of Medicine, Hangzhou City University, Hangzhou, China (L.W., W.S., Y.S., X.Z.).

Drug metabolism and disposition: the biological fate of chemicals

|May 29, 2024

概括

希斯乙化调节食道癌 (EC) 中的药物代谢酶. 在EC下调的CYP4F12与减少的迁移和增加的B细胞透相关,提供了潜在的治疗点.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症基因组学癌症基因组学

背景情况:

目前的食道癌 (EC) 治疗提供了有限的生存益处.
药物代谢酶越来越多地被认为是它们在EC开发和药物反应中的作用.
希斯乙化对EC中这些酶的影响是一个新兴的研究领域.

研究的目的:

在EC中识别通过基因素乙化调节的药物代谢酶.
调查这些酶在EC发展中的分子和临床意义.
探索CYP4F12作为潜在的生物标志物和食道癌的治疗点.

主要方法:

在KYSE-150细胞系上进行RNA测序,以评估三氨酸A治疗后的基因表达变化.
基因素乙化分析 (H3 K18和K27) 和p300依赖性评估.
在癌症基因组图谱和GSE53624数据集的基因分析中,研究CYP4F12表达和患者生存相关性.
用于功能丰富和免疫细胞透评估的基因实体学分析.
开发一个预测性诺莫格拉姆模型,结合临床因素和CYP4F12表达.

主要成果:

CYP4F12通过三静氨酸A升高调节,与其促进体的素H3乙化增加有关,依赖于p300.
在EC瘤组织中,CYP4F12的下调,并与更好的无病生存率相关.
CYP4F12表达与细胞迁移减少和B细胞透增加相关.
高CYP4F12表达与抑制检查点标记有负相关性.
建立了一种结合临床因素和CYP4F12表达的预测性名录.

结论:

CYP4F12在食道癌的发展中起着至关重要的作用.
向CYP4F12可能会提高当前EC疗法的疗效.
CYP4F12作为预后生物标志物和潜在的治疗指南为EC患者.

更多相关视频

Assays for Validating Histone Acetyltransferase Inhibitors

Assays for Validating Histone Acetyltransferase Inhibitors

Published on: August 6, 2020

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Global Level Quantification of Histone Post-Translational Modifications in a 3D Cell Culture Model of Hepatic Tissue

Published on: May 5, 2022

相关概念视频

Spreading of Chromatin Modifications

Spreading of Chromatin Modifications

The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...

Histone Modification

Histone Modification

The histone proteins have a flexible N-terminal tail extending out from the nucleosome. These histone tails are often subjected to post-translational modifications such as acetylation, methylation, phosphorylation, and ubiquitination. Particular combinations of these modifications form “histone codes” that influence the chromatin folding and tissue-specific gene expression.
Acetylation
The enzyme histone acetyltransferase adds acetyl group to the histones. Another enzyme, histone...

Histone Variants at the Centromere

Histone Variants at the Centromere

Histone variants are the histone proteins with structural and sequence variations. These variants may be regarded as “mutant” forms that replace their canonical histone counterparts in the nucleosomes. Specific post-translational modifications on the histone variants enable further chromatin complexity and regulate tissue-specific gene expression. The most common histone variants are from histone H2A, H2B, and linker histone H1 families. However, several variants of histone H3...